PGPIPN
- Category
- Specialized Research
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A casein-derived hexapeptide sold as an immune modulator, said to boost macrophage activity and calm inflammation through mechanisms whose receptor targets remain unconfirmed. Anti-cancer, liver-protective, and chemo-synergy claims rest on low-confidence or speculative animal and cell data. No human trials exist, there is no safety data, and immune stimulation is a theoretical concern in autoimmune disease. Not an approved drug in the US; supply consists of unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(8)
Anti-ovarian cancer activity (direct tumor suppression)
LowInhibited ovarian cancer cells and reduced tumor growth in mice; no human trials yet.
Inhibition of cancer cell invasion and migration
SpeculativeBlocked cancer cell invasion and migration in lab-dish studies only, no animal model tested.
Synergy with cisplatin (chemosensitization)
SpeculativeIncreased cisplatin sensitivity in resistant ovarian cancer cells, single lab-dish study only.
Evidence limits
- Evidence Level
- Preclinical
All published PGPIPN research consists of in vitro cell culture experiments and in vivo mouse model studies. The peptide has been tested against human ovarian cancer cell lines (SKOV3, COC1, and their cisplatin-resistant variants) and primary ovarian cancer cells from over 40 patients, as well as in xenograft nude mouse tumor models and Kunming mouse liver disease models. There are no human pharmacokinetic, safety, efficacy, or dose-finding studies. The original immunomodulation work from the 1980s was also entirely in vitro/animal. The consistent results across multiple independent cell lines and primary patient samples are encouraging, but human translation remains untested.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
No human safety data exists
HighNo standardized pharmaceutical-grade product available
HighPotential immunostimulatory effects may be contraindicated in autoimmune conditions
TheoreticalDairy allergen origin
LowUnknown effects on healthy tissue at high systemic concentrations
ModeratePotential interaction with cancer treatment protocols
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.